Reduced sympatho-vagal responses to orthostatic stress in drug naïve idiopathic restless legs syndrome

Author(s):  
Jung-Won Shin ◽  
Jun-Sang Sunwoo ◽  
Jung-Ick Byun ◽  
Tae-Joon Kim ◽  
Jin-Sun Jun ◽  
...  
SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A300-A301
Author(s):  
H Im

Abstract Introduction Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron-dopamine dysregulation and immune system alteration. Hepcidin is the key regulatory hormone of systemic iron homeostasis and is related to inflammatory processes. We aimed to evaluate the clinical utility of hepcidin as a diagnostic biomarker and index of therapeutic responses in RLS patients after dopaminergic treatment. Methods Non-anemic and drug-naive RLS patients (n=18) and healthy controls (n=15) were enrolled. Hepcidin (pre-prohepcidin) and iron-related values in serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 RLS patients. Information about sociodemographic characteristics, sleep-related profiles, mood, and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. Results Hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at a diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/ml, p = 0.978). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00−0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00−7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression, and anxiety. Conclusion This study demonstrates a role of hepcidin as a predictor of therapeutic responses in RLS patients. Support This work was supported by the Korea Health technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, South Korea [grant number HI17C2072].


2013 ◽  
Vol 19 (3) ◽  
pp. 355-358 ◽  
Author(s):  
Hee-Young Shin ◽  
Jinyoung Youn ◽  
Won Tae Yoon ◽  
Ji Sun Kim ◽  
Jin Whan Cho

SLEEP ◽  
2021 ◽  
Author(s):  
Raffaele Ferri ◽  
Maria P Mogavero ◽  
Oliviero Bruni ◽  
Daniel L Picchietti ◽  
Vidhi Kapoor ◽  
...  

Abstract Study objectives To evaluate leg movements during sleep (LMS) in children taking serotonergic antidepressants, compared to those of children with restless legs syndrome (RLS) and controls, and to assess the time structure of intermovement intervals (IMI). Methods Twenty-three children (12 girls, mean age 14.1 years) on antidepressants and with a total LMS index ≥15/hour, 21 drug-naïve RLS children (11 girls, mean age 13.6 years) also with total LMS index ≥15/hour, and 35 control children (17 girls, mean age 14.3 years) were recruited. LMS were scored and a series of parameters was calculated, along with the analysis of their time structure. Results Children taking antidepressants showed higher total and periodic LMS (PLMS) indexes than both controls and RLS children, as well as higher short-interval and isolated LMS indexes than controls. LMS periodicity was highest in children on antidepressants. In children taking antidepressants, a well-defined PLMS IMI peak corresponding to ~10-60 s, with a maximum at ~20 s was present, which was much less evident in RLS patients and absent in controls. A progressive decrease of PLMS during the night and more frequent arousals were found in children on antidepressants and with RLS. Conclusions Children taking serotonergic antidepressants show higher periodicity LMS than children with RLS or controls and have a higher number of PLMS through the night. Antidepressant-associated PLMS in children seem to have features similar to PLMS of adults with RLS. Whether this is a marker of an increased risk to develop RLS later in life needs to be determined.


2020 ◽  
Vol 9 (12) ◽  
pp. 4115
Author(s):  
Hee-Jin Im ◽  
Jee Hyun Kim ◽  
Chang-Ho Yun ◽  
Dong Wook Kim ◽  
Jeeyoung Oh

Background: Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron–dopamine dysregulation and immune system alteration. We aimed to assess the effects of serum hepcidin, an iron-regulating hormone, in drug-naive RLS patients compared to healthy controls and to evaluate its role in helping to predict clinical improvement after treatment with dopamine agonist. Methods: Nonanemic and drug-naive RLS patients (n = 18) and healthy controls (n = 15) were enrolled. The serum hepcidin and iron-related values in the serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 patients. Information about sociodemographic characteristics, sleep-related profiles, mood and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. Results: Serum hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/mL, p = 0.357). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00−0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00−7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression and anxiety. Conclusions: This study demonstrates the role of hepcidin in evaluating the positive therapeutic response in RLS.


Neurology ◽  
2001 ◽  
Vol 57 (7) ◽  
pp. 1307-1309 ◽  
Author(s):  
I. Eisensehr ◽  
T. C. Wetter ◽  
R. Linke ◽  
S. Noachtar ◽  
H. v. Lindeiner ◽  
...  

2012 ◽  
Vol 19 (5) ◽  
pp. 702-705 ◽  
Author(s):  
Young-Min Lim ◽  
Sung-Eun Chang ◽  
Seockhoon Chung ◽  
Bong-Hui Kang ◽  
Kwang-Kuk Kim

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Keisuke Suzuki ◽  
Masayuki Miyamoto ◽  
Tomoyuki Miyamoto ◽  
Koichi Hirata

Sleep disturbances are important nonmotor symptoms in Parkinson’s disease (PD) that are associated with a negative impact on quality of life. Restless legs syndrome (RLS), which is characterized by an urge to move the legs accompanied by abnormal leg sensations, can coexist with PD, although the pathophysiology of these disorders appears to be different. RLS and PD both respond favorably to dopaminergic treatment, and several investigators have reported a significant relationship between RLS and PD. Sensory symptoms, pain, motor restlessness, akathisia, and the wearing-off phenomenon observed in PD should be differentiated from RLS. RLS in PD may be confounded by chronic dopaminergic treatment; thus, more studies are needed to investigate RLS in drug-naïve patients with PD. Recently, leg motor restlessness (LMR), which is characterized by an urge to move the legs that does not fulfill the diagnostic criteria for RLS, has been reported to be observed more frequently in de novo patients with PD than in age-matched healthy controls, suggesting that LMR may be a part of sensorimotor symptoms intrinsic to PD. In this paper, we provide an overview of RLS, LMR, and PD and of the relationships among these disorders.


Neurology ◽  
2002 ◽  
Vol 59 (4) ◽  
pp. 649-650 ◽  
Author(s):  
G.G. Tribl ◽  
S. Asenbaum ◽  
G. Klosch ◽  
K. Mayer ◽  
R.M. Bonelli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document